You are here: Industry Insights > Tabrecta

News List

Novartis Receives Approval for Five Products from Japanese Ministry of Health americanpharmaceuticalreview
July 10, 2020
Novartis Pharma announced the Japanese Ministry of Health, Labour and Welfare (MHLW) approved five new treatment options for Japanese patients.
FDA approves Tabrecta for treatment of metastatic non-small cell lung cancer europeanpharmaceuticalreview
May 12, 2020
The FDA has approved Tabrecta (capmatinib) for patients with metastatic non-small cell lung cancer whose tumours have a mutation that leads to MET exon 14 skipping.
Novartis gets FDA nod for Tabrecta to treat metastatic NSCLC with METex14 pharmaceutical-business-review
May 11, 2020
Novartis has secured approval from the US Food and Drug Administration (FDA) for its Tabrecta (capmatinib) to treat adult patients metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METex14).
Speedy US approval for Novartis' Tabrecta pharmatimes
May 07, 2020
Novartis' Tabrecta (capmatinib, formerly INC280) has been awarded accelerated approval by the US Food and Drug Administration for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation that leads to MET ex
FDA approves first targetted therapy to treat aggressive form of lung cancer expresspharma
May 07, 2020
The FDA also approved the FoundationOne CDx assay (F1CDx) as a companion diagnostic for Tabrecta.